Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
To observe and access the Effects and safety of terlipressin or high dose
 somatostatin/octreotide when usual dose somatostatin/octreotide fail to achieve hemostasis in
 patients with acute variceal bleeding.
The prognosis information of the patients with acute variceal bleeding will be collected,
 including hemostasis rate, early rebleeding rate, mortality, complications, severity adverse
 events, economic burdens and quality of life, when terlipressin or high dose
 somatostatin/octreotide is used as salvation to patients fail to achieve initial
 hemostasis.The results may help gastroenterologists to make decisions when administering
 vasoactive medicines to those suffered from acute variceal bleeding.
Inclusion Criteria:

 -  Cirrhosis patients admitted to Emergency Department because of acute variceal bleeding

 Exclusion Criteria:

 -  No signs of variceal bleeding are found by endoscopy or portal hypertensive
 gastropathy is responsible for the bleeding

 -  Patients undergo endoscopy after 72h from the beginning of acute variceal bleeding

 -  Patients with hepatorenal syndrome

 -  Patients with ischemia organic cardiopathy (including myocardial infarction or
 unstable angina pectoris) or myocardial ischemia indicated by ECG in the past 6 months

 -  Patients allergic to/with contraindications of vasoactive drugs